Levothyroxine ( DrugBank: Levothyroxine )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
| 78 | Hypopituitarism | 2 |
| 80 | Resistance to thyroid hormone | 1 |
49. Systemic lupus erythematosus
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01276782 (ClinicalTrials.gov) | January 2011 | 12/1/2011 | Levothyroxine in Pregnant SLE Patients | Pilot Double-Blind Placebo Controlled Trial of Levothyroxine in Pregnant Systemic Lupus Erythematosus (SLE) Patients With Autoimmune Thyroid Disease | Systemic Lupus Erythematosus | Drug: Levothyroxine | Johns Hopkins University | New York University School of Medicine;Duke University;University of Chicago;Stanford University | Withdrawn | 18 Years | 45 Years | Female | 0 | Phase 4 | United States |
78. Hypopituitarism
Clinical trials : 494 / Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01574859 (ClinicalTrials.gov) | April 2012 | 7/4/2012 | Central Hypothyroidism and Cardiovascular Risk | Central Hypothyroidism and Cardiovascular Risk Factors | Hypopituitarism | Other: levothyroxine | Rigshospitalet, Denmark | NULL | Completed | N/A | N/A | Both | 200 | N/A | Denmark |
| 2 | EUCTR2004-005184-15-GB (EUCTR) | 24/05/2005 | 29/04/2005 | Central Hypothyroidism and Adjusted Thyroxine dose Study (CHATS): impact of increasing free thyroxine levels in patients with hypopituitarism - CHATS | Central Hypothyroidism and Adjusted Thyroxine dose Study (CHATS): impact of increasing free thyroxine levels in patients with hypopituitarism - CHATS | Central (secondary/tertiary) hypothyroidism (subclinical) | Trade Name: Levothyroxine Product Name: Levothyroxine INN or Proposed INN: Levothyroxine | Christie Hospital NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 80 | United Kingdom |
80. Resistance to thyroid hormone
Clinical trial : 1 / Drugs : 6 - (DrugBank : 3) / Drug target genes : 3 - Drug target pathways : 3
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04868045 (ClinicalTrials.gov) | April 27, 2021 | 28/4/2021 | Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer | Evaluation of The Development of Central Resistance to Thyroid Hormone After Prolonged Exposure to Excess Thyroid Hormone in Thyroid Cancer Patients | Thyroid Cancer | Drug: Thyrotropin Releasing Hormone (TRH);Drug: levothyroxine;Other: Hypothyroidism QOL questionnaire | Memorial Sloan Kettering Cancer Center | NULL | Recruiting | 18 Years | N/A | All | 16 | Phase 1 | United States |